Click any tag below to further narrow down your results
Links
Nvidia Corp. will invest $1 billion over five years to establish a new artificial intelligence laboratory in collaboration with Eli Lilly & Co. The facility, located in Silicon Valley, aims to accelerate the application of AI in the pharmaceutical industry by leveraging Lilly's lab expertise.
- Nvidia will invest $1 billion over five years to build an AI drug discovery lab with Eli Lilly, located in Silicon Valley
- The lab will use Lilly's lab expertise combined with Nvidia's computational tools to predict how compounds interact with biological systems
- The goal is to speed up and cut costs in drug discovery while improving precision in targeting specific diseases
- The deal signals Nvidia's strategic push into healthcare as a growth area beyond its core computing and gaming business
Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.
- Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
- Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
- The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.